Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. EPFA Working Group on Quality Assurance.
about
The anemia of vitamin A deficiency: epidemiology and pathogenesis.Preclinical safety profile of plasma prepared using the INTERCEPT Blood System.Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.The proportion and trend of human immunodeficiency virus infections associated with men who have sex with men from Chinese voluntary blood donors: a systematic review and meta-analysis.An audit of gynaecological procedures in Jehovah's Witnesses in an inner city hospital.Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions.Screening of blood donors for hepatitis C virus RNA with the MagNA Pure-COBAS AmpliScreen method.The first large-scale nucleic acid amplification testing (NAT) of donated blood using multiplex reagent for simultaneous detection of HBV, HCV, and HIV-1 and significance of NAT for HBV.Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies.Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests.Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001.Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies.A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis.Value of retaining HBsAg donor screening where HBV NAT and anti-HBc donor screening applyOn the viral safety of plasma pools and plasma derivativesResidual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives
P2860
Q34608773-47440C66-E9C6-4C92-93EE-1A056ED493D3Q35546427-1C6001DA-E242-491A-A79F-DF4AC859873BQ36078723-06C596C4-7E9D-4BF4-81E7-0EC703A825E1Q38261600-B22CEC01-DD66-486F-A6F1-197FD70A9F6AQ39745984-503AAA50-CB47-4042-8C4C-CA73CF029264Q40383406-7F31B292-E822-436E-80E5-FF6A27D33489Q42987806-B9CDD74E-29D0-4C8C-AA4A-90020D1E68B0Q42994845-13E75022-720F-466F-BB5F-B14DE539CB41Q43035321-41B85A45-26F5-486E-A019-5807775A86A9Q43041997-B3FCE51D-092F-4D9C-B328-C4132A26FAD1Q43047999-DF41E06D-345A-438C-B74A-4AFEA93708D0Q44017424-C639BA6D-DF89-4067-84D1-7640BF147B33Q44710463-8FC70960-D225-4AD4-AB00-7647CF5E35FCQ44931522-0A95454D-D1D5-4FE6-83AC-62F334003816Q46854672-29CD962C-5215-4F35-BE89-50C407518C1DQ57176158-4ED954E9-EBD3-42BB-902C-79C2E6A4678CQ58819161-E0D9A295-B8D4-49E2-AF0F-6E6A2239B9E7Q58999805-19A75C28-1D3F-4876-BDF2-3AD1204300E1
P2860
Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. EPFA Working Group on Quality Assurance.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Results of viral marker screen ...... ng Group on Quality Assurance.
@en
Results of viral marker screen ...... ng Group on Quality Assurance.
@nl
type
label
Results of viral marker screen ...... ng Group on Quality Assurance.
@en
Results of viral marker screen ...... ng Group on Quality Assurance.
@nl
prefLabel
Results of viral marker screen ...... ng Group on Quality Assurance.
@en
Results of viral marker screen ...... ng Group on Quality Assurance.
@nl
P2860
P1433
P1476
Results of viral marker screen ...... ng Group on Quality Assurance.
@en
P2093
Müller-Breitkreutz K
P2860
P304
P356
10.1046/J.1423-0410.2000.7830149.X
P577
2000-01-01T00:00:00Z